Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Metropolis Healthcare Ltd - 542650 - Corrigendum - Limited Review Report On The Unaudited Consolidated Financial Results Of The Company For The Quarter And Nine Months Ended December 31, 2021.

 We refer to our letter dated February 11, 2022 submitting Unaudited Consolidated Financial Results for the quarter and nine months ended December 31, 2021, Auditors' Limited Review Report and the requisite declaration on unmodified opinion (Reference no. MHL/Sec&Legal/2021-22/71) There was a typographical error in the Limited Review Report for the quarter and nine months ended December 31, 2021 that inadvertently referred to Regulation 52(4) read with Regulation 63(2) in addition to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Please find enclosed the correct Limited Review Report for the quarter and nine months ended December 31, 2021.We further state that there is no change in the revenue, profit before tax, profit and earnings per share (EPS) numbers of the Group reported in the Unaudited Consolidated Financial Results submitted to you on February 11, 2022.
12-02-2022

Metropolis Healthcare Q3 net falls 30% at Rs 41 cr

 Revenues, however, increased to Rs 293.1 crore in the period under review as against Rs 274.7 crore in the same period of 2020-21 fiscal
11-02-2022
Bigul

Metropolis Healthcare Ltd - 542650 - Grant Of Restrictive Stock Units ('RSU'S') Under Metropolis - Restrictive Stock Unit Plan, 2020 ('MHL-RSU Plan, 2020')

 Dear Sir/ Madam, This is to inform you that the Nomination and Remuneration Committee of the Board at its meeting held on February 11, 2022, approved the grant of 1,000 Restricted Stock Units (RSU's) pursuant to the MHL-RSU Plan, 2020 to the eligible employees of the Company / Subsidiary(ies). The RSU's granted would vest as per the terms of the plan based on performance parameters as decided by the Committee. The vested RSUs need to be exercised within the exercise period as per the terms of the plan and each such RSU confers a right to receive equal no. of equity shares of the Company.
11-02-2022
Bigul

Metropolis Healthcare Ltd - 542650 - Announcement under Regulation 30 (LODR)-Investor Presentation

 Dear Sir/ Madam, Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a copy of the Investor Presentation for the quarter ended December 31, 2021.
11-02-2022
Bigul

Metropolis Healthcare Ltd - 542650 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Intimation of Press Release
11-02-2022
Bigul

Metropolis Healthcare Ltd - 542650 - Corporate Action-Board approves Dividend

 This is to inform you that the Board of Directors of the Company at their meeting held today have inter-alia approved and declared payment of an Interim Dividend at the rate of Rs. 8/- (Rupees Eight only) per Equity Share on the Face Value of Rs. 2/- (Rupees Two only) per Equity Share for the Financial Year 2021-22.
11-02-2022
Bigul

Metropolis Healthcare Ltd - 542650 - Board Meeting Outcome for Outcome Of Board Meeting Held On Friday, February 11, 2022

 i. Approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2021 and took note of the Limited Review Report issued by the Statutory Auditors on the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2021. ii. Approved and declared payment of an Interim Dividend at the rate of Rs. 8/- (Rupees Eight only) per Equity Share on the Face Value of Rs. 2/- (Rupees Two only) per Equity Share for the Financial Year 2021-22.
11-02-2022
Bigul

Metropolis Healthcare Ltd - 542650 - Financial Results For The Quarter And Nine Months Ended December 31, 2021

 i. Approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2021 and took note of the Limited Review Report issued by the Statutory Auditors on the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2021. The copy of the Unaudited Standalone & Consolidated Financial Results of the Company as approved by the Board of Directors together with the Limited Review Report thereon for the quarter and nine months ended December 31, 2021 is enclosed as Annexure - 1 ii. Approved and declared payment of an Interim Dividend at the rate of Rs. 8/- (Rupees Eight only) per Equity Share on the Face Value of Rs. 2/- (Rupees Two only) per Equity Share for the Financial Year 2021-22.
11-02-2022
Bigul

Metropolis Healthcare Ltd - 542650 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 With reference to the captioned subject and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we wish to inform you that pursuant to the approval of the Board of Directors through Circular Resolution passed on January 14, 2022, the Company has transferred on February 09, 2022, 100 (Hundred) Equity Shares of Dr. Ganesan's Hitech Diagnostic Centre Private Limited ('Hitech') (Wholly owned subsidiary of the Company) to Amin's Pathology Laboratory Private Limited ('Amin's'), a wholly-owned subsidiary of the Company, at a total consideration of Rs. 1,97,333/- (Rupees One Lakh Ninety-Seven Thousand Three Hundred and Thirty-Three Only). Accordingly, post transfer of said Equity Shares of Hitech, the direct holding of the Company in Hitech stand at 99.99% and the balance stake will be held through Amin's, a wholly owned subsidiary of the Company.
09-02-2022
Bigul

Metropolis Healthcare Ltd - 542650 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Dear Sir/Madam, We would like to inform you that Centrum Broking Limited will host an earnings call on behalf of the Company with the analysts and investors at 6.00 PM (IST) on Friday, February 11, 2022 wherein the management of the Company will discuss the Q3FY22 Results and Future outlook as enclosed. This is for your information and appropriate dissemination.
06-02-2022
Next Page
Close

Let's Open Free Demat Account